Following stem cell transplant or treatment with CAR T-cell therapies, patients with hematologic malignancies and coronavirus disease 2019 (COVID-19) tend to have favorable outcomes, especially if they are diagnosed in complete remission (CR) and further out from their cell infusion, according to Miguel-Angel Perales, MD, underscoring that care should not be delayed despite the ongoing pandemic.
Delayed therapy results in patients with relapse or progression of disease who did not receive the intended cellular therapy; [weve seen this happen] in 34% of cases, Perales, chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center (MSKCC), said during a presentation delivered at the 2021 AACR Virtual Meeting on COVID-19 and Cancer.1 Given that we can avoid the risk of nosocomial transmission, I think this clearly indicates that we should be careful about how we manage these patients and not try to delay their care.
In his talk, Perales highlighted registry data detailing the impact of the pandemic on cellular treatment in patients with cancer, outcomes of patients who were infected with the virus and received hematopoietic cell transplantation, and the impact of virus-related delays in care.
Data reported to the ASH Research Collaborative COVID-19 Registry for Hematology, a global reference tool available to the public, showed that as of January 15, 2021, a total of 813 malignant and non-malignant cases of COVID-19 were reported, with just over 500 cases reported in the United States alone.2
When looking at cellular therapies received prior to a diagnosis with the virus, 10 patients had received CAR T-cell therapies (6 recovered, 4 died), 46 patients had undergone allogeneic stem cell transplantation (34 recovered, 7 died, 5 had unknown outcome), and the majority, or 78 patients, had undergone autologous stem cell transplantation (67 recovered, 7 died, 4 had unknown outcome).
An earlier analysis of data collected from this registry showed that among the first 250 patients for whom data were collected, the overall mortality rate was 28% (95% CI, 23%-34%).3 However, in patients with moderate to severe COVID-19 infection, the mortality rate was even higher, at 42% (95% CI, 34%-50%). This is a condition that has significantly impacted our patients with hematologic malignancies, noted Perales.
Another registry, of the Center for International Blood & Marrow Transplant Research (CIBMTR), requires the inclusion of outcomes of patients who have undergone transplantation or received CAR T cells.4 As of January 15, 2021, data for 1258 patients from 195 centers were reported to the registry and showed that 50.08% of patients had undergone allogeneic transplantation and 44.66% had undergone autologous transplantation. Only a small percentage of patients received cell therapy, according to Perales.
The age of patients at the time of infection ranged from less than 20 years to older than 70 years, with the majority of patients between the ages of 60 years and 69 years. When looking at infections by region, 29.35% of cases were reported in the Midwest, 23.44% were reported in the Northeast, and 22.73% were reported in the South. The majority of cases occurred within the first 2 years of their infusion. A total of 614 casesalmost half of all patientshad their infection resolve, while 58 experienced improvement; 187 patients had died.
In a subsequent paper, investigators examined risk factors associated with death from COVID-19 in recipients of allogeneic transplantation based on data from the CIBTR registry.5 Results from the multivariate analysis showed that age greater than 50 years (P = .016), male gender (P = .006), and COVID-19 infection in less than 12 months following transplantation (P = .019) were all significantly associated with increased risk of death.
Interestingly, race and ethnicity were not significant in this series, noted Perales. Similarly, when we look at patients [who have undergone] autologous transplant, the only factor that we saw was the diagnosis of lymphoma versus myeloma. Other factors were not significant.
In another analysis, investigators examined outcomes of patients following transplant who were infected with the virus at MSKCC. Of the first 77 patients diagnosed between March 15, 2020 and May 7, 2020, 37 had undergone autologous transplant, 35 had undergone allogeneic transplant, and 5 had received CAR T-cell therapy.6
The disease distribution was as expected, according to Perales. Thirty-eight percent of patients had plasma cell disease, 23% had acute leukemia, 23% had aggressive non-Hodgkin lymphoma (NHL), 5% had Hodgkin lymphoma, 4% had chronic myeloid leukemia, 4% had myelodysplastic syndrome, and 3% had indolent NHL.
When you look at day [of infection] post infusion, you see there was a significant range, said Perales. In fact, the number of patients were diagnosed with COVID-19 several months or even years after their cell therapy. These are the demographics of 77 patients, but this is representative of the patients that we transplant at our center.
Notably, 44% of patients did not have any comorbidities. Investigators also examined the home medications that patients were receiving at the time of their COVID-19 diagnosis. Here, 10 patients were receiving steroids, 18 were receiving immunomodulatory agents, 4 were receiving anticoagulation agents, and 14 were receiving immunosuppressive drugs.
Almost half, or 48%, of patients had mild COVID-19 infection, so they were not admitted to the hospital. Twenty-six percent of patients had moderate infection, and thus, were admitted to the hospital, while 22% had severe infection and were either admitted to the intensive care unit or died.
In that group, the majority of them actually had active malignancy, unlike the other 2 groups where the majority actually were in remission, said Perales. Patients who required high levels of oxygen [were often those who] had active malignancy.
Results from a univariate analysis looking at the predictors of disease severity revealed significant associations between the presence of comorbidities and infiltrates on imaging at the time of diagnosis. Overall, however, we were able to see favorable outcomes with patients after COVID-19 infection, said Perales. Two-thirds of patients actually had a resolution. We did see 14 deaths, which represented 18% of patients. This was 41% of patients who were admitted, but particularly those with an active malignancy.
Among patients who were admitted to the hospital but had a malignancy that was in remission, the mortality rate was 21%. This was due, in part, to the fact that in many cases, patients or their family members decided to forego aggressive medical care.
Additional data revealed that COVID-19 was linked with a drop in lymphocyte populations across the board, added Perales. Notably, lymphopenia with COVID-19 was not found to impair long-term immune reconstitution in patients who had undergone bone marrow transplant.
When looking at survival in patients after infection with COVID-19, overall outcomes were found to be favorable.
Investigators also examined the risk of nosocomial infections in patients who had undergone transplantation or received cellular treatment in light of the pandemic. They looked at a series of 44 cases.
In March 2020, 2 healthcare workers were exposed at MSKCC and 3 patients had documented COVID-19 infection. One patient was receiving treatment in the inpatient setting, but the patient did have frequent visits from family members, according to Perales. So, its unclear when or how the exposure occurred, Perales said. The patient ended up dying.
Two additional patients may have been exposed in the donor room while they were collecting the stem cell from the autologous transplant, added Perales. One patient eventually died from the virus.
Again, its unclear whether these patients were infected in the center or in the community, as COVID-19 was very prevalent at the time, said Perales. Importantly, we have not seen any additional cases of potential or definite COVID-19 nosocomial infection since March 2020 at our center.
When examining the impact of the pandemic on treatment delays, in March 2020, investigators started to prospectively collect data from patients whose transplant or cellular therapy was delayed as a result of the impact of the virus on resources at the hospital, particularly the capability of using intensive care unit beds.1
Results showed that 85 patients delayed treatment; of those patients, 29 have not received their intended cellular treatment. Sixteen were supposed to receive autologous transplant, 12 were supposed to undergo allogeneic transplant, and 1 was supposed to receive CAR T-cell therapy.
Of the 56 patients who eventually proceeded to treatment, 62% received autologous transplant, 67% received allogeneic transplant, and 86% received CAR T-cell therapy. The biggest reason for not proceeding to treatment with autologous transplant and CAR T-cell therapy was because they were deferred due to good disease control. Other reasons included was because of a new comorbidity (12%) or they died from the virus. The most prominent reason for not proceeding to allogeneic transplant during the pandemic was progression of disease (42%).
We conclude that patients who are recipients of allogeneic transplant, and particularly those with acute leukemia, as much as possible should proceed to their indicated therapy and not be delayed, concluded Perales.
See more here:
- Stem-cell therapy - Wikipedia - December 30th, 2022
- Stem Cell Transplantation: What it Is, Process & Procedure - December 30th, 2022
- Stem Cell Therapy for Arthritis | Arthritis-health - December 30th, 2022
- FDA Warns About Stem Cell Therapies | FDA - U.S. Food and Drug ... - December 30th, 2022
- Induced pluripotent stem cell - Wikipedia - December 30th, 2022
- Stem cell - Wikipedia - November 28th, 2022
- Types of Stem Cell and Bone Marrow Transplants - American Cancer Society - November 28th, 2022
- Novel stem cell therapy for repair of knee cartilage - Mayo Clinic - November 28th, 2022
- Celebrities Are Officially Being Sued by FTX Retail Investors - November 20th, 2022
- FDA Gives First Go Ahead for Lab Grown Meat Product - November 20th, 2022
- Sam Bankman-Fried Admits the "Ethics Stuff" Was "Mostly a Front" - November 20th, 2022
- "Elon" Plummets in Popularity as a Baby Name for Some Reason - November 20th, 2022
- Celebrities' Bored Apes Are Hilariously Worthless Now - November 20th, 2022
- Startup Says It's Building a Giant CO2 Battery in the United States - November 20th, 2022
- Panicked Elon Musk Reportedly Begging Engineers Not to Leave - November 20th, 2022
- Former Facebook Exec Says Zuckerberg Has Surrounded Himself With Sycophants - November 20th, 2022
- Experts Baffled by Why NASA’s “Red Crew” Wear Blue Shirts - November 20th, 2022
- NASA Drops Stunning New James Webb Image of a Star Being Born - November 20th, 2022
- Ticketmaster May Have Finally Met Its Match: Furious Swifties - November 20th, 2022
- Elon Musk Locks Twitter Employees Out Office, Then Asks Them to Meet Him on the 10th Floor - November 20th, 2022
- NASA Tells Astronauts That Tweeting Isn't As Important as Staying Alive - November 20th, 2022
- NASA Orders Press Not to Photograph Launch Site After Moon Mission Takes Off - November 20th, 2022
- Amazing Map Lets You Scroll Through the Entire Known Universe - November 20th, 2022
- Experts Excoriate NASA Report Claiming James Webb Wasn't Homophobic - November 20th, 2022
- So Many People Are Using a Diabetes Drug for Weight Loss That Actual Diabetics Are Having Trouble Getting It - November 20th, 2022
- Behind the Lawsuit Against Celebs Who Shilled FTX Before Its Spectacular Meltdown - November 20th, 2022
- Twitter Claims Video of Moon Rocket Launch Is Revenge Porn - November 20th, 2022
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022
- Global Stem Cell Banking Market Research Report 2022: Market to Reach $11.5 Billion by 2026 - Adult Stem Cell Research Gains Traction, Accelerating... - October 27th, 2022
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 8th, 2022
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 8th, 2022
- Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL - Cancer Network - July 8th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- Global Lupus Market is Expected to Reach USD 4.3 Billion With CAGR of 12.41% By Forecast 2027 Says Maximize Market Research (MMR) - Digital Journal - July 8th, 2022
- Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference - GuruFocus.com - July 8th, 2022
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 8th, 2022
- Global Adrenoleukodystrophy Treatment Market Trends, Growth, Opportunities and Forecast to 2029 Designer Women - Designer Women - July 8th, 2022
- Mayo Clinic Q and A: Stem cell therapy for arthritis ... - November 29th, 2021
- FDA Warns About Stem Cell Therapies | FDA - November 29th, 2021
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - The New York Times - November 29th, 2021
- Cell Therapy Markets, 2030 - ResearchAndMarkets.com - Business Wire - November 29th, 2021
- Neuroplast secures 10 million in funding to boost clinical development of stem cell therapy for traumatic spinal cord injuries - Spinal News... - November 29th, 2021
- Innovating Reversible Cell Therapies With RNA - Technology Networks - November 29th, 2021
- US Stem Cell Therapy Market size and analysis by leading manufacturers, application and types 2021-2027 Energy Siren - Energy Siren - November 29th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 29th, 2021
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 29th, 2021
- Covid vaccine: Stem cell transplant patients who must be completely re-vaccinated struggling to book jabs - iNews - November 29th, 2021
- Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace - November 29th, 2021
- An Against-the-Odds Cancer Story Can Be Yours - Curetoday.com - November 29th, 2021
- Calls for stem cell donation to change in Australia to reduce reliance on overseas donors - ABC News - November 29th, 2021
- The Expanding Role of Interferons in Myeloproliferative Neoplasms - Targeted Oncology - November 29th, 2021
- Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma - OncLive - September 5th, 2021
- Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com - September 5th, 2021
- MD Anderson Now to Offer Solution for Cellular Therapy Toxicities - Targeted Oncology - September 5th, 2021
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - September 5th, 2021
- BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com - September 5th, 2021
- Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News - September 5th, 2021
- Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology - September 5th, 2021
- Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive - September 5th, 2021
- MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch - Newswise - September 5th, 2021